Some people with diabetes are at a greater risk for chronic inflammation, which can damage tissues and harm our health. Dr. Jennie Luna explains how this can occur, and she offers practical lifestyle tips on how to reduce low-grade inflammation.
[read_more text="read more" title="read more" url="https://tcoyd.org/2022/12/c-reactive-protein-and-its-role-in-inflammation-and-diabetes/" align="left"]
SGLT2s have been popular in the type 2 diabetes world for years now, due to their cardiovascular benefits, kidney protection, ability to reduce A1c, and influence on weight loss. Dr. Preethika Ekanayake discusses the benefits (and the risks) for use in T1D.
[read_more text="read more" title="read more" url="https://tcoyd.org/2022/07/sglt2-inhibitors-in-type-1-diabetes-friend-or-foe/" align="left"]
Dr. Edelman discusses the important role ACE inhibitors and ARBs play in protecting your heart and kidneys.
[read_more text="read more" title="read more" url="https://tcoyd.org/2022/04/does-everyone-with-diabetes-need-to-be-on-an-ace-inhibitor/" align="left"]
We are fortunate to have many medications today to treat type 2 diabetes. Beyond improving glucose levels, some of these medications also have beneficial effects on other conditions that are common in people with type 2, such as heart failure and diabetic kidney disease.
[read_more text="read more" title="read more" url="https://tcoyd.org/2021/10/medications-and-other-treatment-options-to-reduce-complications-from-type-2-diabetes/" align="left"]
The FDA recently approved Kerendia, a new medication that addresses the management of certain complications of type 2 diabetes, including chronic kidney disease and cardiovascular disease.
[read_more text="read more" title="read more" url="https://tcoyd.org/2021/09/live-long-and-prosper-with-kerendia-a-new-medication-for-type-2-diabetes/" align="left"]
